[Hypolipidemic effects of DH581 during prolonged administration (author's transl)].
A new cholesterolol lowering agent, DH581, has been studied in eighteen patients with elevated cholesterol levels for more than one year. The data showed twelve patients studied as being cholesterol responders with an overall decrease of 21%. The Placebo period had an overall rise in cholester with a return of effect after re-administration of the drug. During the remainder of the study period, responders had a 17% decrease in cholesterol. Non-responders varied widely but did not demonstrate a significant cholesterol decrease. Triglyceride levels demonstrated wide fluctuation. Nine responders of eighteen patients studied had an overall decrease of 32% and the remainder demonstrated an increase in triglyceride values. Weight changes were not significant and did not account for the observed changes. There was no consistent relationship of sex to the observed response. DH581 appears to be effective antyhypercholesterolemic drug of low toxicity.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000627:therapeutic use*; D010919:Placebos; D011341:Probucol / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D010636:Phenols; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D011341:Probucol
Riduzione della colesterolemia dopo somministrazione prolungata di DH 581